| VVOS 0.196 -12.85% | CLGN 0.3879 8.35% | PCG 13.27 -20.06% | GPRO 0.8762 46.06% | AIM 0.226 -12.54% | NVDA 220.78 1.48% | TSLL 9.97 11.02% | CNH 11.83 1.28% | RDHL 0.9 36.16% | NVD 3.93 -2.96% | NU 14.55 1.75% | BITO 10.63 1.72% | COOT 0.5928 28.87% | AAL 13.43 -1.54% | FNGR 0.223 -43.97% | INTC 89.51 0.04% | SOAR 0.2325 7.19% | NCRA 2.83 49.74% | SPCX 143.69 1.55% | TSLA 367.95 5.51% | PATH 18.67 2.87% | LGCL 0.0351 -9.77% | ABEV 2.87 0.35% | AEHL 6.49 83.33% | PFE 28.46 1.79% | AMZN 259.77 -2.50% | NIO 4.24 -2.97% | NOK 10.14 -0.69% | BAC 61.94 -0.61% | SNAP 5.55 2.21% | KEEL 3.15 -2.17% | IBIT 44.67 1.75% | TQQQ 71.92 0.10% | WETO 5.48 -4.20% | BMNR 25.32 6.39% | AAPL 316.85 -0.89% | PURR 12.25 5.51% | F 13.94 0.43% | WBUY 0.9 8.43% | ROIV 34.64 -0.20% | IREN 37.115 4.70% | CDE 20.78 -1.66% | SPY 767.05 -0.30% | IONQ 39.31 0.28% | T 25.88 -0.50% | HYG 79.81 0.09% | SOFI 17.88 -1.00% | TLT 82.52 -0.43% | SLB 60.1 4.83% | PLUG 2.16 -1.37%

Elevance Health (NYSE:ELV) Delivers Strong Q2 Earnings, Exceeding Market Expectations

Elevance Health (NYSE:ELV) is a major health benefits provider in the United States. It offers a range of health insurance plans and related services. On July 15, 2026, Elevance Health reported its second-quarter earnings results, showing strong financial performance that surpassed market expectations.

The company announced an earnings per share (EPS) of $7.45. This figure significantly beat the analyst consensus estimate of $6.21. As highlighted by Zacks, this also surpassed their consensus estimate of $6.18. However, the result is lower than the $8.84 per share from the same quarter a year ago.

Elevance Health also posted strong revenue of $49.83 billion, which exceeded the estimated $48.84 billion. This represents an increase from the prior year's revenue of $49.42 billion. This report marks the third time Elevance Health has topped revenue estimates in the last four quarters.

Following the strong quarter, Elevance Health is raising its financial outlook. As highlighted by Business Wire, the company now expects its full-year 2026 adjusted EPS to be at least $27.00. Elevance Health also plans to increase investments in medical cost management and member experience.

From a stock valuation standpoint, Elevance Health trades at a price-to-earnings (P/E) ratio of 17.38. The company's debt-to-equity ratio of 0.69 shows it uses a mix of debt and equity to fund operations. Its current ratio of 1.52 indicates a strong ability to meet short-term obligations, reflecting solid financial health and liquidity.

Published on: July 15, 2026